Effect of metformin on apoptosis, cell cycle arrest migration and invasion of A498 cells

Molecular Medicine Reports

Volumn 9, Issue 6, 2014, Pages 2251-2256

  Fang, Zhiqing ^a,b   Xu, Xiulian ^a   Zhou, Zunlin ^a   Xu, Zhonghua ^a   Liu, Zhaoxu ^a,c  

^a SHANDONG UNIVERSITY   (China)

^b Qilu Hospital of Shandong University   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Invasion; Metformin; Migration; Renal cancer

Indexed keywords

CYCLIN D1; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PROTEIN BAX; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; KIDNEY CANCER; METASTASIS INHIBITION; CELL CYCLE CHECKPOINT; CELL MOTION; DRUG EFFECTS; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; METFORMIN;

EID: 84899700999     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2097     Document Type: Article

References (40)

1. Li L, Gao Y, Zhang L, Zeng J, He D and Sun Y: Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett 272: 61-69, 2008.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Bukowski RM: Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80: 1198-1220, 1997.
4. Rabinovitch RA, Zelefsky MJ, Gaynor JJ and Fuks Z: Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 12: 206-212, 1994. (Pubitemid 24020641)
5. Baaten G, Voogd AC and Wagstaff J: A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer. Eur J Cancer 40: 1127-1144, 2004. (Pubitemid 38526331)
6. + lymphocytes correlates with immature tumour angiogenesis in renal cell carcinomas. Asian Pac J Cancer Prev 13: 867-872, 2012.
7. Abe H and Kamai T: Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol 20: 944-955, 2013.
8. Witters LA: The blooming of the French lilac. J Clin Invest 108: 1105-1107, 2001.
9. Ruiter R, Visser LE, van Herk-Sukel MP, et al: Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 35: 119-124, 2012.
10. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH and Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11: 20, 2011.
11. Wu N, Gu C, Gu H, Hu H, Han Y and Li Q: Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 58: 482-490, 2011.
12. Storozhuk Y, Hopmans SN, Sanli T, et al: Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 108: 2021-2032, 2013.
13. Fang Z, Tang Y, Fang J, et al: Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PloS One 8: e62823, 2013.
14. Fang Z, Tang Y, Jiao W, et al: Nitidine chloride inhibits renal cancer cell metastasis via suppressing AKT signaling pathway. Food Chem Toxicol 60: 246-251, 2013.
15. Pollak M: Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 3: 1060-1065, 2010.
16. Dowling RJ, Zakikhani M, Fantus IG, Pollak M and Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812, 2007. (Pubitemid 350145909)
17. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF and Bost F: Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9: 1092-1099, 2010.
18. Xiong Y, Lu QJ, Zhao J and Wu GY: Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. Asian Pac J Cancer Prev 13: 3275-3279, 2012.
19. Goodwin PJ, Ligibel JA and Stambolic V: Metformin in breast cancer: time for action. J Clin Oncol 27: 3271-3273, 2009.
20. Okoshi R, Ozaki T, Yamamoto H, et al: Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 283: 3979-3987, 2008.
21. Chen MB, Wu XY, Gu JH, Guo QT, Shen WX and Lu PH: Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys 60: 311-322, 2011.
22. Liu J, Li M, Song B, et al: Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 31: 264-270, 2013.
23. Senderowicz AM: Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol 16: 670-678, 2004.
24. Schwartz GK and Shah MA: Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23: 9408-9421, 2005.
25. Alao JP: The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24, 2007.
26. Song E, Ma X, Li H, et al: Attenuation of krüppel-like factor 4 facilitates carcinogenesis by inducing g1/s phase arrest in clear cell renal cell carcinoma. PloS One 8: e67758, 2013.
27. Laviolette LA, Wilson J, Koller J, et al: Human folliculin delays cell cycle progression through late S and G2/M-phases: effect of phosphorylation and tumor associated mutations. PloS One 8: e66775, 2013.
28. Circu ML and Aw TY: Glutathione and modulation of cell apoptosis. Biochim Biophys Acta 1823: 1767-1777, 2012.
29. Andersen JL and Kornbluth S: The tangled circuitry of metabolism and apoptosis. Mol Cell 49: 399-410, 2013.
30. Petsophonsakul P, Pompimon W and Banjerdpongchai R: Apoptosis induction in human leukemic promyelocytic HL-60 and monocytic U937 cell lines by goniothalamin. Asian Pac J Cancer Prev 14: 2885-2889, 2013.
31. Smith MA and Schnellmann RG: Calpains, mitochondria, and apoptosis. Cardiovasc Res 96: 32-37, 2012.
32. Czabotar PE, Lessene G, Strasser A and Adams JM: Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15: 49-63, 2014.
33. Hasan TN, B LG, Shafi G, Al-Hazzani AA and Alshatwi AA: Anti-proliferative effects of organic extracts from root bark of Juglans Regia L. (RBJR) on MDA-MB-231 human breast cancer cells: role of Bcl-2/Bax, caspases and Tp53. Asian Pac J Cancer Prev 12: 525-530, 2011.
34. Zhang N, Kong X, Yan S, Yuan C and Yang Q: Huaier aqueous extract inhibits proliferation of breast cancer cells by inducing apoptosis. Cancer Sci 101: 2375-2383, 2010.
35. Zhang N, Wang X, Huo Q, et al: The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) in breast cancer. J Biol Chem 288: 9396-9407, 2013.
36. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nature Rev Mol Cell Biol 9: 47-59, 2008.
37. Himelstein BP, Lee EJ, Sato H, Seiki M and Muschel RJ: Tumor cell contact mediated transcriptional activation of the fibroblast matrix metalloproteinase-9 gene: involvement of multiple transcription factors including Ets and an alternating purine-pyrimidine repeat. Clin Exp Metastasis 16: 169-177, 1998. (Pubitemid 28252924)
38. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7: 3113-3119, 2001. (Pubitemid 32963832)
39. Hu Y and Ivashkiv LB: Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of IFN-alpha dendritic cells. J Immunol 176: 6022-6033, 2006.
40. Gialeli C, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278: 16-27, 2011.